Here’s what you should know:
1. Valeant will use the proceeds of the sale to repay debt under its senior secured credit facility.
2. The transaction could close in the second half of 2017.
3. Valeant estimated Obagi would’ve made $85 million in 2017 full-year revenue.
4. Valeant CEO Joseph C. Papa said in a release, “The sale of Obagi marks additional progress in our efforts to streamline our operations and reduce debt. As we continue to transform Valeant, we will remain focused on the core businesses that will drive high value for our shareholders.”
More articles on improving performance:
Practice Partners in Healthcare, Atlanta Orthopaedic Institute Surgery Center partner on ASC & more — 4 ASC company key notes
Last patient completes RedHill Biopharma’s phase II study for IBS-D treatment — 4 insights
Stock market week-in-review for 5 large GI companies — July 10-July 14
